Middle East And Africa Hereditary Transthyretin Amyloidosis Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 65,985.45 |
 CAGR |
% |
| Major Markets Players |
>中东和非洲遗传性转甲状腺素蛋白淀粉样变性市场，按诊断和治疗（诊断和治疗）、基因变异（V122L、T60A、V30M 等）、性别（男性和女性）、适应症（心肌病（ATTR-CM）、多发性神经病（ATTR-PN）和混合适应症）、最终用户（医院和诊所、诊断实验室、放射中心、学术和研究机构、门诊手术中心和家庭护理）、分销渠道（直接招标、第三方分销商、医院药房、零售药房等） - 行业趋势和预测到 2030 年。
中东和非洲遗传性转甲状腺素淀粉样变性市场分析和规模
由于市场参与者数量的增加和先进技术诊断设备的可用性，预计中东和非洲遗传性转甲状腺素淀粉样变性市场将在预测年内增长。先进技术领域的不断发展有望进一步促进市场增长。然而，治疗药物和诊断及手术用医疗器械的生产和商业化严格规定等困难预计将在预测期内抑制市场增长。
Data Bridge Market Research 分析称，中东和非洲遗传性转甲状腺素淀粉样变性市场预计到 2030 年将达到 65,985.45 万美元的价值，预测期内的复合年增长率为 3.1%。本市场报告还深入介绍了定价分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（千美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
诊断和治疗（诊断和治疗）、基因变异（V122L、T60A、V30M 等）、性别（男性和女性）、适应症（心肌病 (ATTR-CM)、多发性神经病 (ATTR-PN) 和混合适应症）、最终用户（医院和诊所、诊断实验室、放射中心、学术和研究机构、门诊手术中心和家庭护理）、分销渠道（直接招标、第三方分销商、医院药房、零售药房等） |
|
覆盖国家 |
南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东和非洲其他地区 |
|
涵盖的市场参与者 |
辉瑞公司、通用电气医疗集团、西门子医疗有限公司、荷兰皇家飞利浦电子公司、佳能医疗系统株式会社、东软集团、日本光电株式会社、岛津制作所、Alnylam Pharmaceuticals, Inc.、SCHILLER、Novo Nordisk A/S、FONAR Corp 和 MinFound Medical Systems Co. 等 |
市场定义
中东和非洲遗传性转甲状腺素蛋白淀粉样变性市场是一个专注于治疗和诊断 hATTR 的制药和生物技术市场，hATTR 是一种罕见的遗传性疾病，其特征是组织和器官中积累异常的转甲状腺素蛋白，导致各种器官功能障碍。
遗传性转甲状腺素蛋白淀粉样变性 (hATTR) 是一种罕见的遗传性疾病，其特征是异常的转甲状腺素蛋白 (TTR) 在身体的各个组织和器官中积累。TTR 是一种主要在肝脏中产生的蛋白质，负责在血液中运输甲状腺素（一种甲状腺激素）和视黄醇（维生素 A）。在 hATTR 中，基因突变导致 TTR 蛋白错误折叠，使其形成淀粉样纤维并沉积在器官中，从而破坏其正常功能。hATTR 有不同的形式，包括遗传性 ATTR 多发性神经病 (hATTR-PN) 和遗传性 ATTR 心肌病 (hATTR-CM)。在 hATTR-PN 中，周围神经主要受到影响，导致感觉、运动和自主神经功能障碍。患者可能会出现麻木、刺痛、肌肉无力和胃肠道问题等症状。
中东和非洲遗传性转甲状腺素淀粉样变性市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 遗传性转甲状腺素蛋白淀粉样变性患病率上升
遗传性转甲状腺素蛋白淀粉样变性 (hATTR)，又称家族性淀粉样多发性神经病 (FAP)，是一种罕见的遗传性疾病，其特征是淀粉样纤维在身体各个器官和组织中异常积聚。淀粉样纤维是错误折叠的蛋白质，它们会聚集在一起，随着时间的推移会导致器官功能障碍。
甲状腺素运载蛋白 (TTR) 是一种主要由肝脏产生的蛋白质，其正常功能是将甲状腺素（一种甲状腺激素）和视黄醇（一种维生素 A）输送到血液中。在 hATTR 中，基因突变导致甲状腺素运载蛋白变得不稳定，更容易发生错误折叠，从而导致淀粉样蛋白沉积的形成。
由于各种因素，遗传性转甲状腺素蛋白淀粉样变性 (hATTR) 的患病率正在上升。首先，改进的基因检测方法使得识别患有 hATTR 风险的个体变得更容易且更经济实惠，从而可以更早地诊断并更好地了解该疾病的患病率。医务人员和普通民众对 hATTR 的认识不断提高，导致更多病例得到识别和诊断。更好的报告和数据收集正在使对 hATTR 患病率的估计更加准确。
最后，人口老龄化加剧可能是导致 hATTR 患病率上升的原因之一。这种疾病通常发病较晚，随着人口老龄化，越来越多的人可能会出现 hATTR 症状，从而导致报告病例数增加。
- 遗传性转甲状腺素蛋白淀粉样变性的研究和临床试验不断增加
过去几年，针对遗传性转甲状腺素蛋白淀粉样变性 (hATTR) 的研究和临床试验有所增加。科学兴趣的激增可以归因于几个因素，包括我们对该疾病的遗传基础和病理生理学的理解有所进步。研究人员已经确定了与 hATTR 相关的转甲状腺素蛋白基因中的各种突变，这些遗传知识为靶向治疗铺平了道路。
最有希望的 hATTR 治疗方法之一是使用 TTR 稳定剂。这些药物旨在稳定转甲状腺素蛋白，防止其错误折叠并形成淀粉样蛋白原纤维。在临床试验中，这些药物在减缓疾病进展和改善患者生活质量方面显示出良好的效果。
另一个令人兴奋的 hATTR 研究途径是基因沉默疗法，具体来说是 RNA 干扰 (RNAi) 和反义寡核苷酸 (ASO)。这些治疗方法通过减少异常转甲状腺素蛋白的产生，从而减少淀粉样纤维的形成量。早期临床试验已显示出令人鼓舞的结果，一些基因沉默疗法显示血液中异常 TTR 蛋白的水平显著降低。
除了这些方法外，人们还在探索基因编辑技术（例如 CRISPR-Cas9）在治疗 hATTR 方面的潜力。CRISPR-Cas9 可让科学家精确编辑转甲状腺素蛋白基因，纠正或消除致病突变。尽管基因编辑仍处于早期开发阶段，但它有望为 hATTR 提供更持久、更有效的解决方案。
许多国家都建立了患者登记处来支持研究和临床试验，收集 hATTR 患者的数据。这些登记处可帮助研究人员更好地了解该疾病的自然病程、确定临床试验的潜在参与者并跟踪治疗结果。
因此，针对遗传性转甲状腺素蛋白淀粉样变性的研究和临床试验的增加有望成为市场增长的动力。
机会
政府针对遗传性转甲状腺素蛋白淀粉样变性治疗的举措
政府机构越来越认识到解决遗传性转甲状腺素淀粉样变性 (hATTR) 问题的重要性，并为受影响的个人提供更好的支持。这些政府举措是基于这样的认识：hATTR 是一种罕见且严重的遗传病，对患者的生活有重大影响。这些举措旨在提高对 hATTR 的认识、研究、患者护理以及获得有效治疗的机会。
政府举措的一个重要方面是研究资金。政府已拨款支持 hATTR 的科学研究，包括基础科学研究和临床研究。这些资金鼓励科学家和医学研究人员探索该疾病的潜在机制、确定潜在的治疗目标并开发新的治疗方法。政府通过为研究项目提供资金支持，促进对 hATTR 的了解，并可能找到更好的管理和治疗该疾病的方法。
因此，政府针对遗传性转甲状腺素蛋白淀粉样变性治疗的举措有望成为市场增长的机会。
限制/挑战
- 遗传性转甲状腺素蛋白淀粉样变性治疗费用高昂
遗传性转甲状腺素淀粉样变性 (hATTR) 治疗的高昂费用可能会对患者和医疗保健系统造成重大障碍。
多种因素导致开发和提供这些疗法的费用高昂。首先，研发成本是治疗费用高昂的主要原因。开发新药，尤其是针对 hATTR 等罕见疾病的药物，需要在基础研究、临床前研究和临床试验方面进行大量投资。确定潜在药物靶点、进行动物研究和进行多个临床试验阶段的成本可能相当高昂。此外，药物开发早期失败的风险意味着公司必须收回成功和失败的成本，这进一步增加了财务负担。
因此，与遗传性转甲状腺素蛋白淀粉样变性相关的高成本预计会成为市场增长的制约因素。
- 诊断遗传性转甲状腺素蛋白淀粉样变性的复杂性
由于复杂性遗传性运甲状腺素蛋白淀粉样变性 (hATTR) 的临床表现多样且罕见，因此诊断过程十分复杂且具有挑战性。hATTR 是一种由运甲状腺素蛋白 (TTR) 基因突变引起的遗传异质性疾病，导致异常 TTR 蛋白以淀粉样蛋白沉积的形式在各种器官（包括周围神经、心脏和胃肠系统）中积聚。
hATTR 诊断的关键步骤之一是进行基因检测以确定 TTR 基因中的特定突变。然而，已知的 TTR 基因突变有数百种，确定确切的突变可能具有挑战性，需要专门的基因检测和专业知识。基因检测对于区分 hATTR 与其他形式的淀粉样变性（例如野生型 ATTR (ATTRwt) 和 AL 淀粉样变性）尤其重要，这些淀粉样变性可能具有重叠的临床特征。
因此，复杂的遗传性转甲状腺素蛋白淀粉样变性诊断预计将成为市场增长的挑战。
近期发展
- 2022年6月，Alnylam Pharmaceuticals, Inc.获得FDA授权，可使用AMVUTTRA（vutrisiran）治疗遗传性转甲状腺素蛋白介导的淀粉样变性引起的多发性神经病。
- 2023年4月，佳能医疗系统公司宣布已与日本国立癌症中心（NCC）合作，开始采用具有光子计数计算机断层扫描的下一代X射线CT系统进行临床研究。这将有助于该组织开发其产品类别。
- 2022 年 12 月，一项新技术 AIR Recon DL 最近获得了《大众科学》杂志的“最佳新技术”奖。这是 GE Healthcare 开发的一项新技术，可在短时间内提供高质量的图像。AIR Recon DL 使用深度学习技术同时提高 MRI 图像质量并缩短扫描时间，从而改善患者体验。
中东和非洲遗传性转甲状腺素淀粉样变性市场范围
中东和非洲遗传性转甲状腺素蛋白淀粉样变性市场分为六个显著的细分市场：诊断和治疗、基因变异、性别、适应症、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
诊断和治疗
- 诊断
- 治疗
根据诊断和治疗，市场细分为诊断和治疗。
基因变异
- V122 升
- T60A
- V30M
- 其他的
根据基因变异，市场细分为 V122L、T60A、V30M 等。
性别
- 男性
- 女性
根据性别，市场分为男性和女性。
指征
- 心肌病 (ATTR-CM)
- 多发性神经病 (ATTR-PN)
- 混合适应症
根据适应症，市场分为心肌病（ATTR-CM）、多发性神经病（ATTR-PN）和混合适应症。
最终用户
- 医院和诊所
- 诊断实验室
- 放射科中心
- 学术及研究机构
- 门诊手术中心
- 家庭护理
根据最终用户，市场分为医院和诊所、诊断实验室、放射中心、学术和研究机构、门诊手术中心和家庭护理。
分销渠道
- 直接招标
- 第三方分销商
- 医院药房
- 零售药店
- 其他的
根据分销渠道，市场分为直接招标、第三方分销商、医院药房、零售药房等。
中东和非洲遗传性转甲状腺素淀粉样变性市场国家分析/见解
对中东和非洲遗传性转甲状腺素蛋白淀粉样变性市场进行了分析，并通过上述诊断和治疗、基因变异、性别、适应症、最终用户和分销渠道提供了市场规模洞察和趋势。
中东和非洲遗传性转甲状腺素蛋白淀粉样变性市场涵盖的国家包括南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东和非洲其他地区。
由于医疗专业人员和公众对疾病的认识和教育不断提高，南非有望主导市场并成为增长最快的市场，这可能有助于识别和管理诸如遗传性转甲状腺素淀粉样变性等疾病。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了区域品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。
竞争格局和中东和非洲遗传性转甲状腺素淀粉样变性市场份额分析
中东和非洲遗传性转甲状腺素淀粉样变性市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、新市场计划、区域存在、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
在中东和非洲遗传性转甲状腺素蛋白淀粉样变性市场运营的一些主要市场参与者包括辉瑞公司、通用电气医疗集团、西门子医疗有限公司、荷兰皇家飞利浦公司、佳能医疗系统株式会社、东软集团、日本光电株式会社、岛津制作所、Alnylam Pharmaceuticals, Inc.、SCHILLER、Novo Nordisk A/S、FONAR Corp. 和 MinFound Medical Systems Co. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DIAGNOSIS AND TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END-USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 PIPELINE ANALYSIS
5 REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
6.1.2 INCREASING RESEARCH AND CLINICAL TRIALS FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
6.1.3 ADVANCEMENT IN GENE THERAPY
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY APPROVALS FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT
6.2.2 HIGH COST ASSOCIATED WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT
6.3 OPPORTUNITIES
6.3.1 GOVERNMENT INITIATIVES FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT
6.3.2 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.4 CHALLENGES
6.4.1 COMPLEXITY IN DIAGNOSING HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
6.4.2 LIMITED PATIENT POOL FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
7 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET : BY COUNTRIES
8 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, COMPANY LANDSCAPE
8.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
9 SWOT ANALYSIS
10 COMPANY PROFILE
10.1 PFIZER INC.
10.1.1 COMPANY SNAPSHOT
10.1.2 REVENUE ANALYSIS
10.1.3 PRODUCT PORTFOLIO
10.1.4 RECENT DEVELOPMENT
10.2 GE HEALTHCARE.( A SUBSIDARY OF GENERAL ELECTRIC)
10.2.1 COMPANY SNAPSHOT
10.2.2 REVENUE ANALYSIS
10.2.3 PRODUCT PORTFOLIO
10.2.4 RECENT DEVELOPMENT
10.3 SIEMENS HEALTHCARE GMBH
10.3.1 COMPANY SNAPSHOT
10.3.2 REVENUE ANALYSIS
10.3.3 PRODUCT PORTFOLIO
10.3.4 RECENT DEVELOPMENT
10.4 KONINKLIJKE PHILIPS N.V.
10.4.1 COMPANY SNAPSHOT
10.4.2 REVENUE ANALYSIS
10.4.3 PRODUCT PORTFOLIO
10.4.4 RECENT DEVELOPMENT
10.5 CANON MEDICAL SYSTEMS CORPORATION
10.5.1 COMPANY SNAPSHOT
10.5.2 REVENUE ANALYSIS
10.5.3 PRODUCT PORTFOLIO
10.5.4 RECENT DEVELOPMENT
10.6 ALNYLAM PHARMACEUTICALS, INC.
10.6.1 COMPANY SNAPSHOT
10.6.2 REVENUE ANALYSIS
10.6.3 PRODUCT PORTFOLIO
10.6.4 RECENT DEVELOPMENT
10.7 ASTRAZENECA
10.7.1 COMPANY SNAPSHOT
10.7.2 REVENUE ANALYSIS
10.7.3 PRODUCT PORTFOLIO
10.7.4 RECENT DEVELOPMENT
10.8 FONAR CORP.
10.8.1 COMPANY SNAPSHOT
10.8.2 REVENUE ANALYSIS
10.8.3 PRODUCT PORTFOLIO
10.8.4 RECENT DEVELOPMENT
10.9 MINFOUND MEDICAL SYSTEMS CO.,
10.9.1 COMPANY SNAPSHOT
10.9.2 PRODUCT PORTFOLIO
10.9.3 RECENT DEVELOPMENT
10.1 NEUSOFT CORPORATION
10.10.1 COMPANY SNAPSHOT
10.10.2 REVENUE ANALYSIS
10.10.3 PRODUCT PORTFOLIO
10.10.4 RECENT DEVELOPMENT
10.11 NIHON KOHDEN CORPORATION.
10.11.1 COMPANY SNAPSHOT
10.11.2 RECENT FINANCIALS
10.11.3 PRODUCT PORTFOLIO
10.11.4 RECENT DEVELOPMENT
10.12 NOVO NORDISK A/S
10.12.1 COMPANY SNAPSHOT
10.12.2 REVENUE ANALYSIS
10.12.3 PRODUCT PORTFOLIO
10.12.4 RECENT DEVELOPMENT
10.13 SCHILLER
10.13.1 COMPANY SNAPSHOT
10.13.2 PRODUCT PORTFOLIO
10.13.3 RECENT DEVELOPMENT
10.14 SHIMADZU CORPORATION
10.14.1 COMPANY SNAPSHOT
10.14.2 REVENUE ANALYSIS
10.14.3 PRODUCT PORTFOLIO
10.14.4 RECENT DEVELOPMENT
11 QUESTIONNAIRE
12 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, PIPELINE ANALYSIS
TABLE 2 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 22 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 23 SOUTH AFRICA DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND)
TABLE 24 SOUTH AFRICA IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 SOUTH AFRICA NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND)
TABLE 26 SOUTH AFRICA BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 27 SOUTH AFRICA TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 SOUTH AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND)
TABLE 29 SOUTH AFRICA APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 SOUTH AFRICA PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 31 SOUTH AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND)
TABLE 32 SOUTH AFRICA GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 33 SOUTH AFRICA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 34 SOUTH AFRICA PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 35 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND)
TABLE 36 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 37 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND)
TABLE 38 SOUTH AFRICA POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 39 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 40 SOUTH AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 41 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 42 SAUDI ARABIA DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND)
TABLE 43 SAUDI ARABIA IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 SAUDI ARABIA NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND)
TABLE 45 SAUDI ARABIA BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 SAUDI ARABIA TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 47 SAUDI ARABIA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND)
TABLE 48 SAUDI ARABIA APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 SAUDI ARABIA PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 SAUDI ARABIA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND)
TABLE 51 SAUDI ARABIA GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 SAUDI ARABIA MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 53 SAUDI ARABIA PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND)
TABLE 55 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 56 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND)
TABLE 57 SAUDI ARABIA POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 58 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 59 SAUDI ARABIA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 60 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 61 U.A.E DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND)
TABLE 62 U.A.E IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 U.A.E NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND)
TABLE 64 U.A.E BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 U.A.E TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 U.A.E MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND)
TABLE 67 U.A.E APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 U.A.E PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 U.A.E MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND)
TABLE 70 U.A.E GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 71 U.A.E MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 72 U.A.E PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND)
TABLE 74 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 75 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND)
TABLE 76 U.A.E POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 77 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 78 U.A.E HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 79 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 80 EGYPT DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND)
TABLE 81 EGYPT IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 EGYPT NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND)
TABLE 83 EGYPT BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 84 EGYPT TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 EGYPT MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND)
TABLE 86 EGYPT APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 EGYPT PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 EGYPT MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND)
TABLE 89 EGYPT GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 90 EGYPT MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 91 EGYPT PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 92 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND)
TABLE 93 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 94 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND)
TABLE 95 EGYPT POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 96 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 97 EGYPT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 98 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 99 ISRAEL DIAGNOSIS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TESTS, 2021-2030 (USD THOUSAND)
TABLE 100 ISRAEL IMAGING TEST IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 ISRAEL NUCLEAR IMAGING IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY IMAGING TEST, 2021-2030 (USD THOUSAND)
TABLE 102 ISRAEL BIOPSY IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 103 ISRAEL TREATMENT IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 104 ISRAEL MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY APPROVAL, 2021-2030 (USD THOUSAND)
TABLE 105 ISRAEL APPROVED MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 ISRAEL PIPELINE MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 ISRAEL MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY MODE OF ACTION, 2021-2030 (USD THOUSAND)
TABLE 108 ISRAEL GENE SILENCER IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 ISRAEL MEDICATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 110 ISRAEL PARENTERAL IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENE VARIATION, 2021-2030 (USD THOUSAND)
TABLE 112 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 113 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY INDICATION, 2021-2030 (USD THOUSAND)
TABLE 114 ISRAEL POLYNEUROPATHY (ATTR-PN) IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 115 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 116 ISRAEL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 117 REST OF MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: MARKET END-USER COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 THE DIAGNOSIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET
FIGURE 14 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: SNAPSHOT (2022)
FIGURE 15 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
